Related Experiment Video
Updated: Jun 13, 2026
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Discovery of a new potent bisamide FMS kinase inhibitor
Mohammed I El-Gamal1, Myung-Ho Jung, Chang-Hyun Oh
1Biomaterials Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Republic of Korea.
Abstract:
FMS is a type III receptor tyrosine kinase that binds to the macrophage or monocyte colony stimulating factor (M-CSF or CSF-1). Signal transduction through that binding results in survival, proliferation, and differentiation of monocyte/macrophage lineage. In this study, we report the discovery of a new potent inhibitor of FMS kinase. The synthesized pyrrolo[3,2-c]pyridine derivative (compound 1) was initially tested at a single concentration of 1 microM against 47 different kinases. At this concentration, the% inhibitions of the enzymatic activities of FMS and KDR kinases were 90% and 71%, respectively, while the inhibition in activity was less than 58% for all of the other kinases. For compound 1, the IC(50) values against FMS and KDR were 96 and 1058 nM, respectively. So, compound 1 was found to be 11 times more selective for FMS kinase than KDR kinase. Compound 1 can be used as a promising lead for the development of new selective inhibitors of FMS kinase, which can be used as useful therapeutic tools for treatment of several inflammatory and cancer disorders.
Insights
Researchers discovered a new FMS kinase inhibitor, compound 1. This selective pyrrolo[3,2-c]pyridine derivative shows potent inhibition of FMS kinase, offering potential for inflammatory and cancer disorder treatments.
Area of Science:
- Pharmacology and Medicinal Chemistry
- Molecular Biology
- Oncology
Background:
- FMS (colony-stimulating factor 1 receptor) is a receptor tyrosine kinase crucial for monocyte/macrophage survival, proliferation, and differentiation.
- Dysregulation of FMS signaling is implicated in various inflammatory diseases and cancers.
- Development of selective FMS kinase inhibitors is a therapeutic goal.
Purpose of the Study:
- To report the discovery and characterization of a novel, potent inhibitor of FMS kinase.
- To evaluate the selectivity of the synthesized compound against other kinases.
- To assess the potential of the compound as a therapeutic lead for FMS-related disorders.
Main Methods:
- Synthesis of a pyrrolo[3,2-c]pyridine derivative (compound 1).
- In vitro kinase inhibition assays against a panel of 47 kinases at 1 microM concentration.
- Determination of IC50 values for FMS and KDR kinases.
Main Results:
- Compound 1 demonstrated significant inhibition of FMS kinase (90% at 1 microM) and KDR kinase (71% at 1 microM).
- Compound 1 exhibited high selectivity for FMS kinase over KDR kinase, with IC50 values of 96 nM and 1058 nM, respectively (11-fold selectivity).
- Inhibition of other tested kinases was less than 58%.
Conclusions:
- Compound 1 is a potent and selective inhibitor of FMS kinase.
- The pyrrolo[3,2-c]pyridine derivative represents a promising lead for developing novel FMS-targeted therapeutics.
- This compound holds potential for treating inflammatory conditions and various cancers.
